Phase 2 N=17 Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus
Primary: Overall Summary of Adverse Events — 6; 5; 6; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs
Hypotension · Anesthesia
Primary: Number of Participants Who Had Hypotensive Events — 8; 21 Participants — p=0.01
Phase 3 N=2,199 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Atrial Fibrillation
Primary: Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From…
Phase 4 N=28 Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
Plaque Psoriasis
Primary: Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16 — 7; 2 Participants
N/A N=294 Comprehensive vs. Assisted Management of Mood and Pain Symptoms
Pain · Depression · Anxiety
Primary: Composite Z-score of Pain-anxiety-depression Severity — -0.52; -0.65 units on a scale
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Phase 3 N=276 Improving Patient-centered Care Using an Inventory
Primary Care
Primary: Consultation and Relational Empathy (CARE) Measure — 44.69; 41.99 units on a scale — p=0.029
Phase 1 N=160 A Study of Galcanezumab in Healthy Participants.
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Galcanezumab — 31.5; 32.3 micrograms per milliliter (ug/mL)
Phase 2 N=60 Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events — 0; 2 adverse events
N/A N=1,262 A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy
Colorectal Neoplasms
Primary: Adenomas Per Colonoscopy — 1.53; 1.82; 1.55; 1.30 Adenomas per Colonoscopy
Phase 1 N=28 A Study of Ixekizumab in Participants With Plaque Psoriasis
Psoriasis
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 (CYP450) Substrate-Midazolam — 4.56; 4.92; 4.83 nanogram per milliliter (ng/mL)
Phase 4 N=98 Escitalopram Effects on CSF Amyloid Beta
Amyloid Beta Protein
Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL
Phase 2 N=342 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
CINV
Primary: Number of Participants With Delayed Phase Complete Response(CR) — 37; 13; 27; 21 Participants — p=0.004
Phase 2 N=3 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Part 1: Number of Participants Who Experience at Least One Adverse Event (AE) — 3; 6 Participants
Phase 3 N=375 Safety Study of SPARC1104
Spasticity
Primary: Number of Subjects With Adverse Events — 129; 150; 44 Count of participants